- In adults, e-cigarettes are more effective than alternative nicotine-containing products in supporting smoking cessation.
- Editorial points out comparable cessation rates with medication, raises concerns about long-term vaping, advises use for cessation only if FDA-approved treatments fail and with "clear timeline and ‘off ramp’ for use."
Why this matters
- Evidence has been inadequate about efficacy of e-cigarettes vs other nicotine-replacement products (NRPs) for smoking cessation in adults.
- Abstinence, e-cigarettes vs NRP groups:
- 18.0% vs 9.9%.
- Relative risk, 1.83 (95% CI, 1.30-2.58); P<.001.>
- Number needed to treat: 12.
- Similar results in multiple sensitivity analyses and after multivariate adjustment.
- Randomized pragmatic clinical trial (n=886).
- Adults who wanted to quit smoking were randomly assigned to nicotine-replacement product(s) of their choice vs e-cigarettes.
- 4 weeks’ face-to-face support provided.
- Outcome: self-reported abstinence sustained ≥1 year, validated via expired carbon monoxide levels.
- Funding: National Institute for Health Research; Cancer Research UK.
- Incomplete follow-up.
- May not generalize to less motivated or less dependent smokers.